1. Integrate pharmacokinetic-pharmacodynamic (PK-PD) modeling and pharmacogenomics techniques to develop a population PK-PD model, aiming to explore monitoring and dose guidance schemes for Direct Oral Anticoagulants (DOACs).
2. Investigate the factors influencing PK-PD of DOACs in the pulmonary embolism population, clarifying the correlation between genotype characteristics and clinical outcomes.
3. Explore the correlation between drug concentrations, coagulation indices, and clinical outcomes of DOACs, defining the indications for DOACs testing and the overall monitoring process.

Inclusion Criteria:

• Adult patients with acute symptomatic pulmonary embolism objectively diagnosed by imaging (with or without deep vein thrombosis) who have completed anticoagulation for the acute phase and have entered the maintenance phase of anticoagulation
• Expected lifespan greater than 3 months
• Eligible for the use of Xa factor inhibitors;
• Agreement to participate in the study, signing of informed consent, and commitment to regular follow-up.

Exclusion Criteria:

• Moderate or severe liver dysfunction (Child-Pugh grade B or C);
• Severe renal impairment (CrCl < 15 ml/min);
• Pregnant or breastfeeding women;
• Tendency for spontaneous bleeding, such as coagulopathy or thrombocytopenia (PLT < 20×10^9/L);
• Contraindications for the use of other Xa factor inhibitors;
• Patients diagnosed with hereditary thrombophilia and antiphospholipid syndrome.

Patients diagnosed with pulmonary embolism and are using DOACs.

If there is a reasonable data request, you can contact the project leader via email to obtain the data.